Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3109/13625187.2014.894779.11
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: In-vitro study on the effect of ulipristal acetate on human embryo implantation using a trophoblastic spheroid and endometrial cell co-culture model
Title | In-vitro study on the effect of ulipristal acetate on human embryo implantation using a trophoblastic spheroid and endometrial cell co-culture model |
---|---|
Authors | |
Issue Date | 2014 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/13625187.asp |
Citation | The 13th Congress of the European Society of Contraception and Reproductive Health (ESC 2014), Lisbon, Portugal, 28-31 May 2014. In the European Journal of Contraception and Reproductive Health Care, 2014, v. 19 suppl. 1, abstract no. A-124 How to Cite? |
Abstract | Objectives: Ulipristal acetate (UPA), a selective progesterone receptor modulator, has been
introduced for use in emergency contraception. The main mechanism of action is inhibiting or
delaying ovulation. Whether UPA can have secondary action by inhibiting implantation is still
uncertain. The present study examined the effect of UPA on human embryo implantation using an
in-vitro human trophoblastic spheroid and endometrial cell co-culture model.
Method: We studied the effect of UPA on implantation using a trophoblastic spheroidsendometrial
cell attachment assay. The JAr (human choriocarcinoma) and Ishikawa (human
endometrial adenocarcinoma) cell lines were treated with graded concentrations of UPA (0, 0.04,
0.4 and 4μM) for 24 hours. We took the peak serum drug level after oral administration of UPA 30
mg, i.e. 0.4 μM, as the pharmacological concentration, and our experimental range covered tentimes
below and above this. After treatment, the JAr cells were trypsinized and gently shaken at
106rpm overnight to form spheroids of 100-150mm size, which were used as the embryo
surrogate. A confluent monolayer of the Ishikawa cells was used as the endometrium surrogate,
onto which the spheroids were seeded and cultured for 1 hour at 37oC under 5% CO2. The coculture
was then shaked at 140rpm for 10 minutes to remove any unattached spheroids. The
number of attached JAr spheroid was then counted under light microscope. Attachment rate was
defined as the ratio of the number of attached spheroids to the total number seeded. The
experiment was also repeated using cultured primary human endometrial cells (aspirated 7 days
after the LH surge) as the endometrium surrogate, which was co-cultured with trophoblastic
spheroids for 3 hours after treating the respective cells with 4μM UPA. The results were pooled
from 19 and 7 independent repeats for the Ishikawa and primary endometrial cell experiments
respectively.
Results: In the Ishikawa experiments, there was no significant difference in the trophoblastic
spheroid attachment rate after treatment with UPA at 0 (93.0%), 0.04 (93.6%), 0.4 (93.4%) and 4
(91.4%) μM concentrations (p > 0.05). In the primary endometrial cell experiments, again no
significant difference was observed in trophoblastic spheroid attachment rate between the
treatment group (UPA 4μM, 42.1%) compared to the control (without UPA treatment, 48.3%, p >
0.05). Significant suppression of spheroid attachment rate (p < 0.001) was observed in the
positive controls which were set up with methotrexate 5μM treatment.
Conclusions: UPA at pharmacological concentration used for emergency contraception may not
have inhibitory effect on embryo implantation. |
Description | Conference theme: Challenges in Sexual and Reproductive Health Poster Presentation Poster awards |
Persistent Identifier | http://hdl.handle.net/10722/201588 |
ISSN | 2023 Impact Factor: 1.9 2023 SCImago Journal Rankings: 0.735 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, RHW | en_US |
dc.contributor.author | Li, T | en_US |
dc.contributor.author | Li, Y | en_US |
dc.contributor.author | Ng, EHY | en_US |
dc.contributor.author | Yeung, WSB | en_US |
dc.contributor.author | Ho, PC | en_US |
dc.contributor.author | Lee, CKF | en_US |
dc.date.accessioned | 2014-08-21T07:31:26Z | - |
dc.date.available | 2014-08-21T07:31:26Z | - |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | The 13th Congress of the European Society of Contraception and Reproductive Health (ESC 2014), Lisbon, Portugal, 28-31 May 2014. In the European Journal of Contraception and Reproductive Health Care, 2014, v. 19 suppl. 1, abstract no. A-124 | en_US |
dc.identifier.issn | 1362-5187 | - |
dc.identifier.uri | http://hdl.handle.net/10722/201588 | - |
dc.description | Conference theme: Challenges in Sexual and Reproductive Health | - |
dc.description | Poster Presentation | - |
dc.description | Poster awards | - |
dc.description.abstract | Objectives: Ulipristal acetate (UPA), a selective progesterone receptor modulator, has been introduced for use in emergency contraception. The main mechanism of action is inhibiting or delaying ovulation. Whether UPA can have secondary action by inhibiting implantation is still uncertain. The present study examined the effect of UPA on human embryo implantation using an in-vitro human trophoblastic spheroid and endometrial cell co-culture model. Method: We studied the effect of UPA on implantation using a trophoblastic spheroidsendometrial cell attachment assay. The JAr (human choriocarcinoma) and Ishikawa (human endometrial adenocarcinoma) cell lines were treated with graded concentrations of UPA (0, 0.04, 0.4 and 4μM) for 24 hours. We took the peak serum drug level after oral administration of UPA 30 mg, i.e. 0.4 μM, as the pharmacological concentration, and our experimental range covered tentimes below and above this. After treatment, the JAr cells were trypsinized and gently shaken at 106rpm overnight to form spheroids of 100-150mm size, which were used as the embryo surrogate. A confluent monolayer of the Ishikawa cells was used as the endometrium surrogate, onto which the spheroids were seeded and cultured for 1 hour at 37oC under 5% CO2. The coculture was then shaked at 140rpm for 10 minutes to remove any unattached spheroids. The number of attached JAr spheroid was then counted under light microscope. Attachment rate was defined as the ratio of the number of attached spheroids to the total number seeded. The experiment was also repeated using cultured primary human endometrial cells (aspirated 7 days after the LH surge) as the endometrium surrogate, which was co-cultured with trophoblastic spheroids for 3 hours after treating the respective cells with 4μM UPA. The results were pooled from 19 and 7 independent repeats for the Ishikawa and primary endometrial cell experiments respectively. Results: In the Ishikawa experiments, there was no significant difference in the trophoblastic spheroid attachment rate after treatment with UPA at 0 (93.0%), 0.04 (93.6%), 0.4 (93.4%) and 4 (91.4%) μM concentrations (p > 0.05). In the primary endometrial cell experiments, again no significant difference was observed in trophoblastic spheroid attachment rate between the treatment group (UPA 4μM, 42.1%) compared to the control (without UPA treatment, 48.3%, p > 0.05). Significant suppression of spheroid attachment rate (p < 0.001) was observed in the positive controls which were set up with methotrexate 5μM treatment. Conclusions: UPA at pharmacological concentration used for emergency contraception may not have inhibitory effect on embryo implantation. | - |
dc.language | eng | en_US |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/13625187.asp | - |
dc.relation.ispartof | The European Journal of Contraception and Reproductive Health Care | en_US |
dc.rights | The European Journal of Contraception and Reproductive Health Care. Copyright © Informa Healthcare. | - |
dc.title | In-vitro study on the effect of ulipristal acetate on human embryo implantation using a trophoblastic spheroid and endometrial cell co-culture model | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Li, RHW: raymondli@hku.hk | en_US |
dc.identifier.email | Ng, EHY: nghye@hku.hk | en_US |
dc.identifier.email | Yeung, WSB: wsbyeung@hkucc.hku.hk | en_US |
dc.identifier.email | Ho, PC: pcho@hku.hk | en_US |
dc.identifier.email | Lee, CKF: ckflee@hku.hk | en_US |
dc.identifier.authority | Li, RHW=rp01649 | en_US |
dc.identifier.authority | Ng, EHY=rp00426 | en_US |
dc.identifier.authority | Yeung, WSB=rp00331 | en_US |
dc.identifier.authority | Ho, PC=rp00325 | en_US |
dc.identifier.authority | Lee, CKF=rp00458 | en_US |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.3109/13625187.2014.894779.11 | - |
dc.identifier.hkuros | 234753 | en_US |
dc.identifier.volume | 19 | - |
dc.identifier.issue | suppl. 1 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1362-5187 | - |